> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Recommended Hep A GamaSTAN Dose Increased
- URL: https://www.fdaweb.com/recommended-hep-a-gamastan-dose-increased/
- Published: 2017-09-06T12:00:00.000Z
- Updated: 2026-09-14T22:47:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5139558

FDA says it is recommending an increase in dosing of Grifols Therapeutics’ GamaSTAN S/D (immune globulin \[human\]) when used for hepatitis A (HAV) prophylaxis. An agency [notice](https://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm574795.htm?ref=fdaweb.com) says the dosage increase is based on recently observed decreasing concentrations of antibodies to hepatitis A in GamaSTAN S/D attributed to the decreasing prevalence of previous hepatitis A infection among plasma donors. “This change in the dosage recommendations for HAV prophylaxis is a precautionary measure, to ensure continued effectiveness of GamaSTAN S/D,” the notice says.

The recommended increase for household and institutional hepatitis A contacts is from a prior dose of 0.02 mL/kg to the new dose of 0.1 mL/kg. The notice also contains a chart with dosing recommendations for various lengths of stay as part of travel in areas where hepatitis A is common.